Specialty Business Services
Compare Stocks
5 / 10Stock Comparison
ACTG vs XOMA vs RPRX vs IDCC vs QCOM
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Software - Application
Semiconductors
ACTG vs XOMA vs RPRX vs IDCC vs QCOM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Specialty Business Services | Biotechnology | Biotechnology | Software - Application | Semiconductors |
| Market Cap | $454M | $490M | $21.52B | $7.18B | $213.51B |
| Revenue (TTM) | $215M | $52M | $2.44B | $829M | $44.49B |
| Net Income (TTM) | $-18M | $29M | $828M | $366M | $9.92B |
| Gross Margin | 104.9% | 94.3% | 74.1% | 83.4% | 54.8% |
| Operating Margin | -18.7% | 21.8% | 65.1% | 49.6% | 25.5% |
| Forward P/E | 21.4x | 36.7x | 9.9x | 38.8x | 18.8x |
| Total Debt | $100M | $132M | $8.95B | $506M | $16.37B |
| Cash & Equiv. | $307M | $83M | $619M | $739M | $7.84B |
ACTG vs XOMA vs RPRX vs IDCC vs QCOM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | May 26 | Return |
|---|---|---|---|
| Acacia Research Cor… (ACTG) | 100 | 113.9 | +13.9% |
| XOMA Royalty Corp. (XOMA) | 100 | 212.0 | +112.0% |
| Royalty Pharma plc (RPRX) | 100 | 104.6 | +4.6% |
| InterDigital, Inc. (IDCC) | 100 | 493.7 | +393.7% |
| QUALCOMM Incorporat… (QCOM) | 100 | 240.2 | +140.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACTG vs XOMA vs RPRX vs IDCC vs QCOM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ACTG is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 133.2%, EPS growth 161.1%, 3Y rev CAGR 68.9%
- Lower volatility, beta 0.76, Low D/E 17.2%, current ratio 9.18x
- 133.2% revenue growth vs IDCC's -4.0%
XOMA has the current edge in this matchup, primarily because of its strength in quality and momentum.
- 56.4% margin vs ACTG's -8.5%
- +68.7% vs IDCC's +32.4%
RPRX is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- Dividend streak 2 yrs, beta 0.45, yield 1.3%
- Beta 0.45, yield 1.3%, current ratio 0.97x
- Lower P/E (9.9x vs 18.8x), PEG 1.40 vs 9.06
- Beta 0.45 vs QCOM's 1.55
IDCC is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 436.7% 10Y total return vs QCOM's 350.2%
- PEG 0.74 vs QCOM's 9.06
QCOM ranks third and is worth considering specifically for dividends and efficiency.
- 1.7% yield, 23-year raise streak, vs XOMA's 0.7%, (1 stock pays no dividend)
- 18.4% ROA vs ACTG's -2.4%, ROIC 29.1% vs 1.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 133.2% revenue growth vs IDCC's -4.0% | |
| Value | Lower P/E (9.9x vs 18.8x), PEG 1.40 vs 9.06 | |
| Quality / Margins | 56.4% margin vs ACTG's -8.5% | |
| Stability / Safety | Beta 0.45 vs QCOM's 1.55 | |
| Dividends | 1.7% yield, 23-year raise streak, vs XOMA's 0.7%, (1 stock pays no dividend) | |
| Momentum (1Y) | +68.7% vs IDCC's +32.4% | |
| Efficiency (ROA) | 18.4% ROA vs ACTG's -2.4%, ROIC 29.1% vs 1.2% |
ACTG vs XOMA vs RPRX vs IDCC vs QCOM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ACTG vs XOMA vs RPRX vs IDCC vs QCOM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ACTG leads in 1 of 6 categories
IDCC leads 1 • RPRX leads 1 • QCOM leads 1 • XOMA leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — XOMA and RPRX each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
QCOM is the larger business by revenue, generating $44.5B annually — 853.1x XOMA's $52M. XOMA is the more profitable business, keeping 56.4% of every revenue dollar as net income compared to ACTG's -8.5%. On growth, XOMA holds the edge at +57.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $215M | $52M | $2.4B | $829M | $44.5B |
| EBITDAEarnings before interest/tax | -$8M | $14M | $1.5B | $489M | $12.8B |
| Net IncomeAfter-tax profit | -$18M | $29M | $828M | $366M | $9.9B |
| Free Cash FlowCash after capex | $52M | $3M | $2.6B | $580M | $12.5B |
| Gross MarginGross profit ÷ Revenue | +104.9% | +94.3% | +74.1% | +83.4% | +54.8% |
| Operating MarginEBIT ÷ Revenue | -18.7% | +21.8% | +65.1% | +49.6% | +25.5% |
| Net MarginNet income ÷ Revenue | -8.5% | +56.4% | +33.9% | +44.2% | +22.3% |
| FCF MarginFCF ÷ Revenue | +24.4% | +5.4% | +107.0% | +70.0% | +28.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -56.4% | +57.9% | +11.0% | -2.4% | -3.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -164.0% | +157.8% | -100.0% | -38.0% | +173.0% |
Valuation Metrics
ACTG leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 21.4x trailing earnings, ACTG trades at a 47% valuation discount to QCOM's 40.4x P/E. Adjusting for growth (PEG ratio), IDCC offers better value at 0.45x vs QCOM's 19.44x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $454M | $490M | $21.5B | $7.2B | $213.5B |
| Enterprise ValueMkt cap + debt − cash | $248M | $538M | $29.9B | $6.9B | $222.0B |
| Trailing P/EPrice ÷ TTM EPS | 21.39x | 28.28x | 27.89x | 23.62x | 40.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 36.74x | 9.90x | 38.80x | 18.84x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.12x | 3.95x | 0.45x | 19.44x |
| EV / EBITDAEnterprise value multiple | 4.98x | 37.50x | 19.09x | 12.91x | 15.91x |
| Price / SalesMarket cap ÷ Revenue | 1.59x | 9.39x | 9.05x | 8.61x | 4.82x |
| Price / BookPrice ÷ Book value/share | 0.78x | 8.85x | 2.89x | 8.73x | 10.56x |
| Price / FCFMarket cap ÷ FCF | 7.75x | 170.55x | 8.64x | 13.58x | 16.65x |
Profitability & Efficiency
Evenly matched — ACTG and IDCC and QCOM each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
QCOM delivers a 40.2% return on equity — every $100 of shareholder capital generates $40 in annual profit, vs $-3 for ACTG. ACTG carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMA's 1.57x. On the Piotroski fundamental quality scale (0–9), ACTG scores 9/9 vs RPRX's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -3.2% | +31.9% | +8.5% | +33.4% | +40.2% |
| ROA (TTM)Return on assets | -2.4% | +12.1% | +4.3% | +17.7% | +18.4% |
| ROICReturn on invested capital | +1.2% | +7.4% | +6.7% | +40.9% | +29.1% |
| ROCEReturn on capital employed | +0.9% | +5.2% | +8.7% | +38.1% | +28.9% |
| Piotroski ScoreFundamental quality 0–9 | 9 | 5 | 4 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.17x | 1.57x | 0.92x | 0.46x | 0.77x |
| Net DebtTotal debt minus cash | -$206M | $49M | $8.3B | -$233M | $8.5B |
| Cash & Equiv.Liquid assets | $307M | $83M | $619M | $739M | $7.8B |
| Total DebtShort + long-term debt | $100M | $132M | $9.0B | $506M | $16.4B |
| Interest CoverageEBIT ÷ Interest expense | -5.51x | 2.90x | 3.37x | 11.48x | 17.60x |
Total Returns (Dividends Reinvested)
IDCC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IDCC five years ago would be worth $40,308 today (with dividends reinvested), compared to $7,908 for ACTG. Over the past 12 months, XOMA leads with a +68.7% total return vs IDCC's +32.4%. The 3-year compound annual growth rate (CAGR) favors IDCC at 52.1% vs ACTG's 6.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +25.8% | +47.5% | +29.8% | -14.1% | +17.6% |
| 1-Year ReturnPast 12 months | +53.3% | +68.7% | +56.0% | +32.4% | +42.9% |
| 3-Year ReturnCumulative with dividends | +19.7% | +126.1% | +48.5% | +251.7% | +96.4% |
| 5-Year ReturnCumulative with dividends | -20.9% | +30.0% | +32.4% | +303.1% | +58.5% |
| 10-Year ReturnCumulative with dividends | +2.5% | +186.7% | +22.9% | +436.7% | +350.2% |
| CAGR (3Y)Annualised 3-year return | +6.2% | +31.3% | +14.1% | +52.1% | +25.2% |
Risk & Volatility
RPRX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RPRX is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than QCOM's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RPRX currently trades 97.2% from its 52-week high vs IDCC's 67.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.69x | 1.16x | 0.43x | 1.11x | 1.64x |
| 52-Week HighHighest price in past year | $5.27 | $42.81 | $51.65 | $412.60 | $223.66 |
| 52-Week LowLowest price in past year | $3.03 | $22.29 | $32.15 | $205.78 | $121.99 |
| % of 52W HighCurrent price vs 52-week peak | +89.3% | +96.4% | +97.2% | +67.6% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 57.4 | 71.1 | 66.3 | 30.8 | 80.1 |
| Avg Volume (50D)Average daily shares traded | 343K | 242K | 3.0M | 393K | 15.1M |
Analyst Outlook
QCOM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACTG as "Buy", XOMA as "Buy", RPRX as "Buy", IDCC as "Buy", QCOM as "Hold". Consensus price targets imply 52.5% upside for IDCC (target: $425) vs -13.6% for QCOM (target: $175). For income investors, QCOM offers the higher dividend yield at 1.70% vs IDCC's 0.63%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $53.75 | $53.75 | $425.00 | $175.00 |
| # AnalystsCovering analysts | 7 | 10 | 11 | 16 | 69 |
| Dividend YieldAnnual dividend ÷ price | — | +0.7% | +1.3% | +0.6% | +1.7% |
| Dividend StreakConsecutive years of raises | 0 | 0 | 2 | 4 | 23 |
| Dividend / ShareAnnual DPS | — | $0.30 | $0.68 | $1.76 | $3.44 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.3% | +5.7% | +1.4% | +4.1% |
ACTG leads in 1 of 6 categories (Valuation Metrics). IDCC leads in 1 (Total Returns). 2 tied.
ACTG vs XOMA vs RPRX vs IDCC vs QCOM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ACTG or XOMA or RPRX or IDCC or QCOM a better buy right now?
For growth investors, Acacia Research Corporation (ACTG) is the stronger pick with 133.
2% revenue growth year-over-year, versus -4. 0% for InterDigital, Inc. (IDCC). Acacia Research Corporation (ACTG) offers the better valuation at 21. 4x trailing P/E, making it the more compelling value choice. Analysts rate Acacia Research Corporation (ACTG) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ACTG or XOMA or RPRX or IDCC or QCOM?
On trailing P/E, Acacia Research Corporation (ACTG) is the cheapest at 21.
4x versus QUALCOMM Incorporated at 40. 4x. On forward P/E, Royalty Pharma plc is actually cheaper at 9. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: InterDigital, Inc. wins at 0. 74x versus QUALCOMM Incorporated's 9. 06x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ACTG or XOMA or RPRX or IDCC or QCOM?
Over the past 5 years, InterDigital, Inc.
(IDCC) delivered a total return of +303. 1%, compared to -20. 9% for Acacia Research Corporation (ACTG). Over 10 years, the gap is even starker: IDCC returned +438. 2% versus ACTG's +1. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ACTG or XOMA or RPRX or IDCC or QCOM?
By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.
43β versus QUALCOMM Incorporated's 1. 64β — meaning QCOM is approximately 280% more volatile than RPRX relative to the S&P 500. On balance sheet safety, Acacia Research Corporation (ACTG) carries a lower debt/equity ratio of 17% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — ACTG or XOMA or RPRX or IDCC or QCOM?
By revenue growth (latest reported year), Acacia Research Corporation (ACTG) is pulling ahead at 133.
2% versus -4. 0% for InterDigital, Inc. (IDCC). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -44. 2% for QUALCOMM Incorporated. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ACTG or XOMA or RPRX or IDCC or QCOM?
XOMA Royalty Corp.
(XOMA) is the more profitable company, earning 60. 8% net margin versus 7. 6% for Acacia Research Corporation — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65. 6% versus 2. 2% for ACTG. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ACTG or XOMA or RPRX or IDCC or QCOM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, InterDigital, Inc. (IDCC) is the more undervalued stock at a PEG of 0. 74x versus QUALCOMM Incorporated's 9. 06x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Royalty Pharma plc (RPRX) trades at 9. 9x forward P/E versus 38. 8x for InterDigital, Inc. — 28. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDCC: 52. 5% to $425. 00.
08Which pays a better dividend — ACTG or XOMA or RPRX or IDCC or QCOM?
In this comparison, QCOM (1.
7% yield), RPRX (1. 3% yield), XOMA (0. 7% yield), IDCC (0. 6% yield) pay a dividend. ACTG does not pay a meaningful dividend and should not be held primarily for income.
09Is ACTG or XOMA or RPRX or IDCC or QCOM better for a retirement portfolio?
For long-horizon retirement investors, Royalty Pharma plc (RPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
43), 1. 3% yield). QUALCOMM Incorporated (QCOM) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RPRX: +24. 2%, QCOM: +382. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ACTG and XOMA and RPRX and IDCC and QCOM?
These companies operate in different sectors (ACTG (Industrials) and XOMA (Healthcare) and RPRX (Healthcare) and IDCC (Technology) and QCOM (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ACTG is a small-cap high-growth stock; XOMA is a small-cap high-growth stock; RPRX is a mid-cap quality compounder stock; IDCC is a small-cap quality compounder stock; QCOM is a large-cap quality compounder stock. XOMA, RPRX, IDCC, QCOM pay a dividend while ACTG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.